The overarching political priority for generic drug firms at the moment is creation of a pathway for follow-on biologics. But the industry also hopes that general healthcare reform efforts provide an opportunity to consolidate gains the sector has made around small molecule products as well
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
